anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

130,681-130,740 of 319,975

filter-aware
353
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
354
The slide uses a Q&A format to highlight expert skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
355
The slide uses a Q&A format to build a case for market substitution risk.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
356
The slide uses a Q&A transcript format to highlight low adoption rates and physician skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
357
The slide uses a 'villain' narrative by framing a specific researcher (Jennifer Miller) and patient families as a 'cult' driving artificial demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
358
The slide uses a Q&A format to highlight skepticism among medical professionals regarding a drug's marketing presentation.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
359
The slide uses direct quotes to undermine the credibility of the company's sales representatives and the drug's market reception.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
360
The slide uses a summary headline followed by a verbatim quote with key phrases highlighted in yellow.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
361
The slide uses direct quotes from a pediatric endocrinologist to undermine the viability of a drug (Vykat/diazoxide).Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
362
The slide uses direct quotes from a pediatric endocrinologist to highlight concerns about the clinical management of diabetes risk associated with the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
363
The slide highlights a discrepancy between the company's sales pitch and clinical best practices as perceived by an expert.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
364
The slide uses verbatim quotes from a consultation call to highlight a discrepancy between the company's risk management (handouts) and the physician's expectations of transient vs. permanent side effects.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
365
The slide uses direct quotes from an endocrinologist to undermine the product's differentiation and pricing justification.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
366
The slide uses direct quotes to highlight a potential discrepancy between marketing claims and clinical reality.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
367
The slide highlights a direct contradiction between the company's marketing (Vykat) and expert clinical opinion.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
368
The slide highlights the physician's skepticism and the administrative hurdles faced with the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
369
The slide highlights the endocrinologist's reluctance to prescribe the drug, noting that patient pressure was a primary driver for his involvement.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
370
The slide uses a Q&A format to expose that the drug's popularity is manufactured by advocacy groups rather than medical demand.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
371
The slide uses a Q&A transcript format to expose potential conflicts of interest between a company (Soleno) and a patient association.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
372
The slide uses a Q&A transcript format to highlight potential misinformation or manipulation by study investigators regarding drug efficacy timelines.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
373
The slide uses direct quotes to frame the expert's skepticism and clinical concerns about the drug's safety profile.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
374
The slide uses a Q&A transcript format to expose potential flaws in clinical trial methodology and physician sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
375
The slide uses highlighted text to emphasize key phrases from the expert's transcript.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
376
The slide uses Q&A transcripts to undermine the value proposition of the company's product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
377
The slide uses a Q&A format to expose a gap in the company's support infrastructure.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
378
The slide uses a 'before-after' narrative structure to expose the contradiction between the physician's initial interest and his clinical assessment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
379
The slide uses a direct quote from a pediatric endocrinologist to undermine the drug's clinical value.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
380
The slide uses direct quotes to expose the contradiction between the physician's knowledge of drug inefficacy and their continued prescription behavior.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
381
The slide uses direct quotes from an expert consultation to contrast grassroots patient enthusiasm with professional indifference.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
382
The slide uses a Q&A transcript format to highlight the physician's frustration and lack of guidance from the manufacturer.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
383
The slide presents a quote from an anonymous pediatric endocrinologist criticizing Dr. Miller's influence and medical recommendations.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
384
The slide uses a pull-quote style to highlight the expert's hesitation and lack of full support.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
385
The slide highlights a potential safety concern raised by an expert, specifically regarding pre-diabetic and obese patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
386
The slide presents a Q&A format where the expert questions the company's motives and the clinical rationale for their product.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
387
The slide uses Q&A transcripts to undermine the credibility of the company's marketing claims.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
388
The slide uses a combination of summary text and direct interview transcripts to build a case against the drug's adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
389
The slide uses a Q&A format to highlight expert skepticism regarding the drug's necessity and cost-effectiveness.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
390
The slide highlights a negative expert opinion on a drug being repurposed for PWS.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
391
The slide uses a 'quote-sandwich' technique: a summary paragraph followed by verbatim Q&A transcripts with highlighted key phrases.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
392
The slide uses direct quotes and Q&A excerpts to build a case against the safety of the drug Vykat in the context of PWS treatment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
393
The slide uses highlighted text to emphasize key concerns about Vykat's safety profile and Miller's private skepticism.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
394
The slide uses expert interview transcripts to undermine the value proposition of the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
395
The slide uses a Q&A format to highlight the physician's reluctance to prescribe Vykat and their familiarity with the risks of diazoxide.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
396
The slide uses direct quotes from a pediatric endocrinologist to undermine the company's commercial narrative.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
397
The slide uses direct quotes to build a case against the company's commercial execution.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
398
The slide uses a Q&A format to expose the contradiction between the drug's intended use and its actual clinical viability.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
399
The slide uses direct quotes from an expert consultation to illustrate market resistance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
400
The slide uses a combination of summary bullet points and verbatim Q&A transcripts to highlight the expert's negative assessment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
401
The slide uses a direct quote to undermine the perceived value of the drug.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
402
The slide highlights a potential competitive threat to Vykat from generic diazoxide.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
403
The slide highlights a contradiction between the drug's intended use and its physiological impact on a vulnerable patient population.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
404
The slide uses a summary paragraph followed by a direct quote, highlighting the expert's negative sentiment.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
405
The slide uses direct quotes from an expert consultation to highlight the drug's perceived lack of efficacy and the barrier of administrative burden.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
406
The slide uses a Q&A format to highlight physician reluctance.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
407
The slide presents a summary of an expert interview, highlighting the endocrinologist's preference for GLP-1s over Vykat for PWS patients.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
408
The slide uses direct quotes from an endocrinologist to frame potential medical risks as a barrier to adoption.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
409
The slide uses direct quotes to build a narrative of expert doubt.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
410
The slide uses Q&A transcripts to highlight the expert's skepticism regarding Vykat's value proposition.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
411
The slide uses a Q&A format to highlight the administrative burden and slow approval process for the drug Vykat.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit
412
The slide uses a Q&A transcript format to validate the claim of trial unblinding.Soleno Therapeutics (SLNO) · Scorpion Capital
Activist deck Short seller 1 hit